- Home
- GCTK vs ENVB Comparison
GCTK vs ENVB Comparison
Compare GCTK & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- ENVB
- Stock Information
- Founded
- GCTK 2001
- ENVB 1994
- Country
- GCTK United States
- ENVB United States
- Employees
- GCTK N/A
- ENVB N/A
- Industry
- GCTK Medical/Dental Instruments
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- ENVB Health Care
- Exchange
- GCTK Nasdaq
- ENVB Nasdaq
- Market Cap
- GCTK 3.7M
- ENVB 3.1M
- IPO Year
- GCTK N/A
- ENVB N/A
- Fundamental
- Price
- GCTK $6.01
- ENVB $1.32
- Analyst Decision
- GCTK
- ENVB Strong Buy
- Analyst Count
- GCTK 0
- ENVB 1
- Target Price
- GCTK N/A
- ENVB $10.00
- AVG Volume (30 Days)
- GCTK 1.7M
- ENVB 154.2K
- Earning Date
- GCTK 08-12-2025
- ENVB 08-11-2025
- Dividend Yield
- GCTK N/A
- ENVB N/A
- EPS Growth
- GCTK N/A
- ENVB N/A
- EPS
- GCTK N/A
- ENVB N/A
- Revenue
- GCTK N/A
- ENVB N/A
- Revenue This Year
- GCTK N/A
- ENVB N/A
- Revenue Next Year
- GCTK N/A
- ENVB N/A
- P/E Ratio
- GCTK N/A
- ENVB N/A
- Revenue Growth
- GCTK N/A
- ENVB N/A
- 52 Week Low
- GCTK $5.11
- ENVB $1.01
- 52 Week High
- GCTK $3,756.00
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- GCTK 42.88
- ENVB 52.44
- Support Level
- GCTK $5.11
- ENVB $1.18
- Resistance Level
- GCTK $6.05
- ENVB $1.37
- Average True Range (ATR)
- GCTK 0.59
- ENVB 0.06
- MACD
- GCTK 0.07
- ENVB 0.01
- Stochastic Oscillator
- GCTK 28.22
- ENVB 75.68
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.